Eli Lilly's Retatrutide Achieves 22.6% Weight Loss in Phase 3 Trial, But Fails to Demonstrate Cardiovascular Risk Reduction
Retatrutide, a Triple-Action Agent, Demonstrates Potent Weight Loss Efficacy
Eli Lilly (LLY)'s next-generation obesity treatment, retatrutide, has successfully met the primary endpoints in its Phase 3 trial. This drug is the first triple agonist with a mechanism that simultaneously stimulates GIP, GLP-1, and glucagon receptors. In the TRIUMPH-3 clinical trial, which involved 1,949 patients with severe obesity and cardiovascular disease, the retatrutide 12mg group showed an average weight loss of 22.6% at 80 weeks, demonstrating overwhelming efficacy compared to the placebo group's 3.2%. The TRIUMPH-2 study, which included obese patients with type 2 diabetes, also recorded a 20.8% weight loss.
Differences in Weight Loss Based on Patient Characteristics and Clinical Significance
The achieved weight loss is encouraging, but it is slightly lower than the 28.3% observed in TRIUMPH-1, which targeted obese patients without diabetes, and the 28.7% in TRIUMPH-4, which targeted patients with arthritis. Healthcare professionals and investors should note that this difference in weight loss may be due to the unique metabolic characteristics of high-risk patients. Patients with type 2 diabetes or cardiovascular disease generally have more severe metabolic dysfunction compared to general obese patients, resulting in lower weight loss rates and limits. Therefore, this result has analytical significance in that it achieved a groundbreaking weight loss effect of over 20% even in high-risk groups.
Cardiovascular Risk Reduction Data Fails to Achieve Statistical Significance
However, the fact that retatrutide did not demonstrate statistically significant cardiovascular risk reduction is disappointing. In the TRIUMPH-3 study, the major adverse cardiovascular events (MACE-5) were 44 in the retatrutide group and 52 in the placebo group, resulting in a hazard ratio (HR) of 0.82, but this did not create a statistically significant difference. Eli Lilly explained that this was because the incidence of cardiovascular events in both groups was lower than expected. However, this makes it somewhat more difficult to gain a competitive advantage over Novo Nordisk's Wegovy, which has already demonstrated cardiovascular benefits (20% reduction in MACE) and expanded insurance coverage.
Treatment Discontinuation Rate Due to Adverse Effects and Additional Metabolic Improvement Benefits
The safety profile of the drug is also an important factor in shaping the prescription market, as much as its excellent efficacy. In the 12mg group of the TRIUMPH-3 study, 13.5% of patients discontinued treatment due to adverse effects, showing a slightly higher dropout rate than in previous trials. The main cause was gastrointestinal adverse reactions. In TRIUMPH-2, 33.6% of patients reported diarrhea, and 38% reported nausea. On the other hand, the fact that retatrutide administration improved cardiovascular metabolic indicators by reducing triglycerides by 37% and hs-CRP (high-sensitivity C-reactive protein) by 51.2% can be a positive factor in future approval reviews.
Planned Application in 2027 and Positioning in the Ultra-High Potency Market
Lilly announced that it plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 based on this clinical data. Analysts predict that retatrutide's peak annual sales will be approximately $6.6 billion, and they expect high blockbuster potential. However, due to the ambiguous cardiovascular risk reduction and high risk of adverse effects, it is expected to penetrate the market in a limited way in the ultra-high potency treatment area, targeting primarily highly obese patients who are difficult to treat with existing treatments, rather than as a first-line treatment. Researchers and industry experts see overcoming the tolerability limitations, such as the 13.5% discontinuation rate due to adverse effects and high gastrointestinal adverse effects, as the next challenge. Lilly needs to refine the positioning of this drug, which is expected to generate $6.6 billion in annual revenue, to minimize the erosion effect on existing drugs like Zepbound.
The completion of the Phase 3 trial for retatrutide foreshadows a shift in the global obesity treatment market, projected to reach $150 billion by 2035. In the short term, its 22.6% weight loss efficacy suggests a potential FDA application in Q1 2027. However, the failure to demonstrate statistical significance in MACE-5 (HR 0.82) poses challenges for long-term market share expansion. Given that Novo Nordisk's Wegovy has already secured reimbursement based on a 20% reduction in cardiovascular risk, retatrutide is likely to target a niche market of ultra-high potency treatments for patients with severe obesity who do not respond well to existing therapies, rather than aiming for broad prescription coverage. Researchers and industry observers see overcoming the tolerability limitations, including a 13.5% discontinuation rate due to adverse effects and high rates of gastrointestinal side effects, as a key challenge for the next generation of obesity treatments. Lilly needs to refine the positioning of this drug, which is expected to generate $6.6 billion in annual revenue, to minimize the erosion effect on its existing drug, Zepbound.